Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Cholvax in Bangladesh
NCT02742558Phase 2Completed
- Sponsor
- icddr,b
- Start
- Apr 2016
- Primary completion
- Jun 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Cholvax in cholera (2 arms), sponsored by icddr,b. Primary endpoints: Number of participants with vaccine related reactogenicity at 30 minutes, Number of participants with solicited adverse events at 7 days and 2 more. Started Apr 2016; status: completed.
02
Drugs
Cholvax
03
Conditions
cholera
Beyond the preview
Go deeper on NCT02742558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02742558.